Publication

Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis

Nature Metabolism 2(5):413–431, 2020

Boland ML, Laker RC, Mather K, Nawrocki A, Oldham S, Boland BB, Lewis H, Conway J, Naylor J, Guionaud S, Feigh M, Veidal SS, Lantier L, McGuinness OP, Grimsby J, Rondinone CM, Jermutus L, Larsen MR, Trevaskis JL, Rhodes CJ

View publication

Subjects
Therapeutic AreaDIO mouseMouseTargetCompoundMethod/EndpointAMLN DIO-MASH mouseSpeciesAMLN ob/ob-MASH mouseBody weightBlood biochemistryMetabolic dysfunction-associated steatohepatitisCotadutideGLP-1 receptorGlucagon receptorHistopathology scoreIntraperitoneal glucose tolerance test (IPGTT)Image analysisLiver biopsyLiver morphometryReal-time food intake/activity analysisLiraglutideObeticholic acid

Share this page

Resource Library

Related resources
Publication
Hepatoprotective effects of the long-acting FGF21 analogue PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH
Publication
Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease
Publication
Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis
Poster
Prophylactic and therapeutic hepatoprotective effects of semaglutide in the CDAA-HFD mouse model of advanced NASH with progressive fibrosis

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top